Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Fusion Pharmaceuticals Inc (FUSN)

Fusion Pharmaceuticals Inc (FUSN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 338,382
  • Shares Outstanding, K 42,457
  • Annual Sales, $ 0 K
  • Annual Income, $ -78,330 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.25
Trade FUSN with:

Options Overview

Details
  • Implied Volatility 66.00%
  • Historical Volatility 87.56%
  • IV Percentile 62%
  • IV Rank 57.28%
  • IV High 108.02% on 03/15/21
  • IV Low 9.65% on 04/06/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 9
  • Volume Avg (30-Day) 68
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 583
  • Open Int (30-Day) 257

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.39
  • Number of Estimates 4
  • High Estimate -0.32
  • Low Estimate -0.45
  • Prior Year -2.99
  • Growth Rate Est. (year over year) +86.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.85 +0.51%
on 06/23/21
10.40 -24.13%
on 06/15/21
-0.49 (-5.85%)
since 05/24/21
3-Month
6.61 +19.41%
on 05/18/21
11.13 -29.11%
on 04/05/21
-3.11 (-28.27%)
since 03/24/21

Most Recent Stories

More News
Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434

Ontario and , /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced...

FSNN : 0.0580 (-19.44%)
FUSN : 7.89 (-1.00%)
Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. as Senior Vice President, Research

HAMILTON, ON and BOSTON, /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines,...

FSNN : 0.0580 (-19.44%)
FUSN : 7.89 (-1.00%)
Fusion Pharmaceuticals Enters into Agreement to Build Radiopharmaceutical Manufacturing Facility

, ON and , /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced...

FSNN : 0.0580 (-19.44%)
FUSN : 7.89 (-1.00%)
Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results and Business Update

COMTEX_386335180/2669/2021-05-11T07:30:42

FSNN : 0.0580 (-19.44%)
FUSN : 7.89 (-1.00%)
Fusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusion's Targeted Alpha Therapy (TAT) in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors Expressing IGF-1R

, ON and , /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced...

FSNN : 0.0580 (-19.44%)
MRK : 76.17 (+0.78%)
FUSN : 7.89 (-1.00%)
Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference

HAMILTON, ON and BOSTON, /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines,...

FSNN : 0.0580 (-19.44%)
FUSN : 7.89 (-1.00%)
Fusion Pharmaceuticals Announces Preclinical Combination Data Demonstrating Enhanced Efficacy in Multiple Preclinical Tumor Models

HAMILTON, ON and BOSTON, /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines,...

FSNN : 0.0580 (-19.44%)
FUSN : 7.89 (-1.00%)
Fusion Pharmaceuticals Announces Closing of Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen

, ON and , /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced...

FSNN : 0.0580 (-19.44%)
FUSN : 7.89 (-1.00%)
IPN : 34.71 (-0.54%)
IPSEY : 27.7700 (+1.87%)
Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors

, ON and , /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines today announced...

FSNN : 0.0580 (-19.44%)
FUSN : 7.89 (-1.00%)
Fusion Pharmaceuticals Announces Fourth Quarter 2020 Financial Results and Business Update

Fusion Pharmaceuticals Announces Fourth Quarter 2020 Financial Results and Business Update

FSNN : 0.0580 (-19.44%)
FUSN : 7.89 (-1.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company focused on developing radiopharmaceuticals as precision medicines. The compnay's lead program includes FPI-1434, which is in clinical trial. Fusion Pharmaceuticals Inc. is based in Hamilton, Canada.

See More

Key Turning Points

3rd Resistance Point 8.68
2nd Resistance Point 8.49
1st Resistance Point 8.23
Last Price 7.89
1st Support Level 7.78
2nd Support Level 7.59
3rd Support Level 7.33

See More

Last Price 7.89
52-Week High N/A
Fibonacci 61.8% 14.27
Fibonacci 50% 12.80
Fibonacci 38.2% 11.34
52-Week Low N/A

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar